Cited by 3,848Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel, Walde, David, Wolff, Robert A., Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Open this paper in CoChat — free account

Abstract

Purpose: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. Results: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. Conclusion: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.9525

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Flagged first, then by citations

Show all 49 references

1 of the 49 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 1,008

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
Yung, W. K. A., Vredenburgh, J. J., Cloughesy, T. F., Nghiemphu, P. L., Klencke, B. J., GILBERT, M. R., Reardon, D. A., & Prados, M. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq072 · Cited by 137
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
Mehrotra, S., Britten, C. D., Chin, S. H., Garrett-Mayer, E. S., Cloud, C. A., Li, M., Scurti, G. M., Salem, M. L., Nelson, M. H., Thomas, M. B., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0459-2 · Cited by 140
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
Demols, A., Peeters, M., Polus, M., Maréchal, R., Gay, F., Monsaert, E., Hendlisz, A., & Laethem, J. V. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602966 · Cited by 138
Pancreatic cancer stromal biology and therapy
Xie, D., & Xie, K. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.01.002 · Cited by 139
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
Rahma, O. E., Duffy, A. G., Liewehr, D. J., Steinberg, S. M., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt166 · Cited by 137
Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Tabernero, J. M., Chiorean, E. G., Infante, J. R., Hingorani, S. R., Ganju, V., Weekes, C. D., Scheithauer, W., Ramanathan, R. K., Goldstein, D., Penenberg, D. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0394 · Cited by 142
Self-citation
Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer
Khan, S., Setua, S., Kumari, S., Dan, N., Massey, A. E., Hafeez, B. B., Yallapu, M. M., Stiles, Z. E., Alabkaa, A., Yue, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.005 · Cited by 136
Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma
Rothenberg, M. L., LaFleur, B., Levy, D. E., Washington, M. K., Morgan-Meadows, S., Ramanathan, R. K., Berlin, J. D., Benson, A. B., & Coffey, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0536 · Cited by 136
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
Wöll, S., Schlitter, A. M., Dhaene, K., Roller, M., Esposito, I., Şahin, U., & Türeci, Ö. (2013) · International Journal of Cancer · doi:10.1002/ijc.28400 · Cited by 135
NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
Burtness, B. A., Anadkat, M. J., Basti, S., Hughes, M., Lacouture, M. E., McClure, J. S., Myskowski, P. L., Jennifer, P., Perlis, C., Saltz, L. B., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0074 · Cited by 135
Metabolism addiction in pancreatic cancer
Blum, R., & Kloog, Y. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.38 · Cited by 138
The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression
Thomas, R. M., Toney‐Earley, K., Fenoglio‐Preiser, C. M., Revelo-Penafiel, M. P., Hingorani, S. R., Tuveson, D. A., Waltz, S. E., & Lowy, A. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4128 · Cited by 134
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway
Xu, F., Huang, M., Chen, Q., Niu, Y., Hu, Y., Hu, P., Chen, D., He, C., Huang, K., Zeng, Z., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0281 · Cited by 133
Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies
Teague, A. S., Lim, K., & Wang‐Gillam, A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014564775 · Cited by 135
Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment
Yang, F., Chen, J., Subedi, S., Lee, C. L., Wang, Q., Jiang, Y., Li, J., Yang, D., & Fu, D. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.003 · Cited by 133
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
Chiaravalli, M., Reni, M., & O'Reilly, E. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.007 · Cited by 137
A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer
Aier, I., Semwal, R., Sharma, A., & Varadwaj, P. K. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.12.001 · Cited by 139
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer
Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 136
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
Cascinu, S., Berardi, R., Labianca, R., Siena, S., Falcone, A., Aitini, E., Barni, S., Costanzo, F. D., Dapretto, E., Tonini, G., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70383-2 · Cited by 133
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Schultheis, B. S., Reuter, D., Ebert, M., Siveke, J. T., Kerkhoff, A., Berdel, W. E., Hofheinz, R., Behringer, D. M., Schmidt, W. E., Göker, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx343 · Cited by 134
Chemotherapy and radiotherapy for advanced pancreatic cancer
Chin, V. T., Nagrial, A. M., Sjoquist, K. M., O'Connor, C. A., Chantrill, L. A., Biankin, A. V., Scholten, R. J. P. M., & Yip, D. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011044.pub2 · Cited by 131
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Kang, J., Hwang, I., Yoo, C., Kim, K., Jeong, J. H., Chang, H.-M., Lee, S. S., Park, D. H., Song, T. J., Seo, D. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0598-5 · Cited by 131
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 129
Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study
Jakacki, R. I., Hamilton, M., Gilbertson, R. J., Blaney, S. M., Tersak, J. M., Krailo, M., Ingle, A. M., Voss, S. D., Dancey, J. E., & Adamson, P. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2306 · Cited by 130
Therapeutic options for the management of pancreatic cancer
Rossi, M. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11142 · Cited by 130
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
Akita, H., Zheng, Z., Takeda, Y., Kim, C. Y., Kittaka, N., Kobayashi, S., Marubashi, S., Takemasa, I., Nagano, H., Dono, K., et al. (2009) · Oncogene · doi:10.1038/onc.2009.158 · Cited by 129
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
Zhang, D., LaFortune, T. A., Krishnamurthy, S., Esteva, F. J., Cristofanilli, M., Liu, P., Lucci, A., Singh, B., Hung, M., Hortobágyi, G. N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0951 · Cited by 129
Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells
Pan, X., Arumugam, T., Yamamoto, T., Levin, P. A., Ramachandran, V., Ji, B., Lopez‐Berestein, G., Vivas‐Mejía, P. E., Sood, A. K., McConkey, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1539 · Cited by 129
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
Heinemann, V., Labianca, R., Hinke, A., & Louvet, C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm283 · Cited by 127
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma
Lee, J., Jang, K., Ki, C., Lim, T., Park, Y. S., Lim, H. Y., Choi, D., Kang, W. K., Park, K., & Park, J. O. (2007) · Cancer · doi:10.1002/cncr.22559 · Cited by 127
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
Gresham, G. K., Wells, G. A., Gill, S., Cameron, C., & Jonker, D. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-471 · Cited by 126
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
Cao, P., Maira, S.-M., Garcı́a-Echeverrı́a, C., & Hedley, D. W. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604995 · Cited by 125
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
Hong, J. Y., Nam, E. M., Lee, J., Park, J. O., Lee, S., Song, S.-Y., Choi, S. H., Heo, J. S., Park, S. H., Lim, H. Y., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2328-1 · Cited by 125
Adherence to CONSORT Adverse Event Reporting Guidelines in Randomized Clinical Trials Evaluating Systemic Cancer Therapy: A Systematic Review
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy
Cerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S. M., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 124
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
Marco, M. D. (2010) · Oncology Reports · doi:10.3892/or_00000749 · Cited by 125
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 129
Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma
Reni, M., Cereda, S., Balzano, G., Passoni, P., Rognone, A., Fugazza, C., Mazza, E. A., Zerbi, A., Carlo, V. D., & Villa, E. (2009) · Cancer · doi:10.1002/cncr.24302 · Cited by 125
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials
Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., & Tagliaferri, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.019 · Cited by 124
Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
Delpu, Y., Hanoun, N., Lulka, H., Sicard, F., Sèlves, J., Buscail, L., Torrisani, J., & Cordelier, P. (2011) · Current Genomics · doi:10.2174/138920211794520132 · Cited by 137
Tumour–stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies
Heinemann, V., Reni, M., Ychou, M., Richel, D. J., Macarulla, T. M., & Ducreux, M. P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.004 · Cited by 123
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors
Sinha, S., Vegesna, R., Mukherjee, S., Kammula, A. V., Dhruba, S. R., Wu, W., Kerr, D. L., Nair, N. U., Jones, M. G., Yosef, N., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00756-7 · Cited by 136
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition
Rakhit, A. K., Pantze, M. P., Fettner, S. H., Jones, H. M., Charoin, J., Riek, M., Lum, B. L., & Hamilton, M. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0396-z · Cited by 122
18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy
Schellenberg, D. D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P. L., Ford, J. M., Fisher, G. A., Goodman, K. A., Koong, A. C., & Chang, D. T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.049 · Cited by 121
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
Heinemann, V., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302759 · Cited by 119
Relevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 121
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 126
Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery
Li, J., Wientjes, M. G., & Au, J. L. ‐. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9181-5 · Cited by 120
Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma
Cranmer, L. D., Engelhardt, C., & Morgan, S. S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0210 · Cited by 125
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Samuel, N., & Hudson, T. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.215 · Cited by 117
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Ko, A. H., Bekaii‐Saab, T., Ziffle, J. V., Mirzoeva, O. K., Joseph, N. M., Talasaz, A. H., Kühn, P., Tempero, M. A., Collisson, E. A., Kelley, R. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0979 · Cited by 121
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
Buck, E. A., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P. J., & Iwata, K. K. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0007 · Cited by 119
Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Herbst, R. S., Bajorin, D. F., Bleiberg, H., Blum, D., Hao, D., Johnson, B. E., Ozols, R. F., Demetri, G. D., Ganz, P. A., Kris, M. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8678 · Cited by 119
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
Valsecchi, M. E., McDonald, M., Brody, J. R., Hyslop, T., Freydin, B., Yeo, C. J., Solomides, C., Peiper, S. C., & Witkiewicz, A. K. (2011) · Cancer · doi:10.1002/cncr.26661 · Cited by 118
Current Standards of Chemotherapy for Pancreatic Cancer
Saung, M. T., & Zheng, L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.015 · Cited by 122
Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
Kaida, M., Morita‐Hoshi, Y., Soeda, A., Wakeda, T., Yamaki, Y., Kojima, Y., Ueno, H., Kondo, S., Morizane, C., Ikeda, M., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb65b9 · Cited by 118
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer
Morgan, M. A., Parsels, L. A., Kollar, L. E., Normolle, D. P., Maybaum, J., & Lawrence, T. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4072 · Cited by 118
Predictive approaches for drug combination discovery in cancer
Tonekaboni, S. A. M., Ghoraie, L. S., Manem, V. S., & Haibe‐Kains, B. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw104 · Cited by 118
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 121
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network
Hainsworth, J. D., Spigel, D. R., Farley, C. P., Thompson, D. S., Shipley, D. L., & Greco, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3047 · Cited by 117
Neutrophil‐to‐lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients
Xue, P., Kanai, M., Mori, Y., Nishimura, T., Uza, N., Kodama, Y., Kawaguchi, Y., Takaori, K., Matsumoto, S., Üemoto, S., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.204 · Cited by 116
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Miyazawa, M., Ohsawa, R., Tsunoda, T., Hirono, S., Kawai, M., Tani, M., Nakamura, Y., & Yamaue, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01416.x · Cited by 117
Characterization of zolbetuximab in pancreatic cancer models
Türeci, Ö., Mitnacht‐Kraus, R., Wöll, S., Yamada, T., & Şahin, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1523096 · Cited by 116
First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical Findings
Buscail, L., Bournet, B., Vernejoul, F., Cambois, G., Lulka, H., Hanoun, N., Dufresne, M., Meulle, A., Vignolle‐Vidoni, A., Ligat, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.1 · Cited by 122
Hedgehog signaling and therapeutics in pancreatic cancer
Kelleher, F. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq280 · Cited by 114
Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting
Pothuraju, R., Rachagani, S., Junker, W. M., Chaudhary, S., Saraswathi, V., Kaur, S., & Batra, S. K. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0963-4 · Cited by 119
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Oddo, J., Vitek, M. P., Lopez, C., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0542 · Cited by 114
Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF
Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
“Indeed, EGFR inhibitors have shown limited but reproducible responses in PDAC patients, leading to FDA approval of erlotinib for treating PDAC (Moore et al., 2007).”
Background
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
Wang, J. P., Wu, C., Yeh, Y.-C., Shyr, Y., Wu, Y.-Y., Kuo, C., Hung, Y., Chen, M., Lee, W., Luo, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4216 · Cited by 115
Multiple Layer‐by‐Layer Lipid‐Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models
Li, F., Zhao, X. L., Wang, H., Zhao, R., Ji, T., Ren, H., Anderson, G. J., Nie, G., & Hao, J. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201401583 · Cited by 117
Stromal expression of SPARC in pancreatic adenocarcinoma
Neuzillet, C., Tijeras‐Raballand, A., Cros, J. F., Faivre, S. J., Hammel, P. R., & Raymond, É. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9439-3 · Cited by 114
Systemic treatment of advanced pancreatic cancer
Heinemann, V., Haas, M., & Boeck, S. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.004 · Cited by 111
Multi-Institutional Experience with FOLFIRINOX in Pancreatic Adenocarcinoma
Peddi, P. F., Lubner, S. J., McWilliams, R. R., Tan, B. R., Picus, J., Sorscher, S. M., Suresh, R., Lockhart, A. C., Wang, J., Menias, C. O., et al. (2012) · PubMed · doi:10.6092/1590-8577/913 · Cited by 113
MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential
Rawat, M., Kadian, K., Gupta, Y. A., Kumar, A., Chain, P., Kovbasnjuk, O. N., Kumar, S., & Parasher, G. (2019) · Genes · doi:10.3390/genes10100752 · Cited by 118
When are ‘positive’ clinical trials in oncology truly positive?
Ocana, A., & Tannock, I. F. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq463 · Cited by 110
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Bekaii‐Saab, T., Markowitz, J., Prescott, N. L., Sadée, W., Heerema, N. A., Wei, L., Zunyan Dai, Y., Papp, A. C., Campbell, A., Culler, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0465 · Cited by 112
Metabolism considerations for kinase inhibitors in cancer treatment
Duckett, D. R., & Cameron, M. D. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506873 · Cited by 113
Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor
Ozaki, N., Ohmuraya, M., Hirota, M., Ida, S., Wang, J., Takamori, H., Higashiyama, S., Baba, H., & Yamamura, K. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0567 · Cited by 112
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
Bonnetain, F., Dahan, L., Maillard, E., Ychou, M., Mitry, E., Hammel, P. R., Legoux, J.-L., Rougier, P. R., Bedenne, L., & Seitz, J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.023 · Cited by 111
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 118
Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues
Mohelníková-Duchoňová, B., Brynychová, V., Oliverius, M., Honsová, E., Kala, Z., Múčková, K., & Souček, P. (2013) · Pancreas · doi:10.1097/mpa.0b013e318279b861 · Cited by 111
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity
Berndsen, R. H., Weiss, A., Abdul, U. K., Wong, T. J., Meraldi, P., Griffioen, A. W., Dyson, P. J., & Nowak-Sliwinska, P. M. (2017) · Scientific Reports · doi:10.1038/srep43005 · Cited by 113
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Scheffler, M., Gion, P. D., Doroshyenko, O., Wolf, J., & Fuhr, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587020-000000000-00000 · Cited by 110
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
Jackman, D. M., Kindler, H. L., Yeap, B. Y., Fidias, P. M., Salgia, R., Lucca, J. V., Morse, L. K., Ostler, P. A., Johnson, B. E., & Janne, P. A. (2008) · Cancer · doi:10.1002/cncr.23617 · Cited by 109
Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma
Einama, T., Kamachi, H., Nishihara, H., Homma, S., Kanno, H., Takahashi, K., Sasaki, A., Tahara, M., 岡田, 邦., Muraoka, S., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e318221bed8 · Cited by 109
Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements
Delitto, D., Pham, K., Vlada, A. C., Sarosi, G. A., Thomas, R. M., Behrns, K. E., Liu, C., Hughes, S. J., Wallet, S. M., & Trevino, J. G. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.01.016 · Cited by 111
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Davis, S. L., Cardin, D. B., Shahda, S., Lenz, H., Dotan, E., O’Neil, B. H., Kapoun, A. M., Stagg, R., Berlin, J. D., Messersmith, W. A., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00824-1 · Cited by 112
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 115
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68
Yu, Y., Galanis, C., Woo, Y., Chen, N. G., Zhang, Q., Fong, Y., & Szalay, A. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0533 · Cited by 108
Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells
Black, P. C., Brown, G. A., Inamoto, T., Shrader, M., Arora, A., Siefker-Radtke, A. O., Adam, L., Theodorescu, D., Wu, X., Munsell, M. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1593 · Cited by 109
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Plotkin, S. R., Halpin, C. F., McKenna, M. J., Loeffler, J. S., Batchelor, T. T., & Barker, F. G. (2010) · Otology & Neurotology · doi:10.1097/mao.0b013e3181eb328a · Cited by 108
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31603 · Cited by 104
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
Boeck, S. H., Jung, A., Laubender, R. P., Neumann, J. H. L., Egg, R., Goritschan, C., Vehling‐Kaiser, U., Winkelmann, C., von Weikersthal, L. F., Clemens, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.495 · Cited by 107
Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients
Didolkar, M. S., Coleman, C. W., Brenner, M. J., Chu, K. U., Olexa, N., Stanwyck, E., Yu, A., Neerchal, N. K., & Rabinowitz, S. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1323-7 · Cited by 107
Sorafenib: Where Do We Go from Here?
Siegel, A. B., Olsen, S. K., Magun, A. M., & Brown, R. S. (2010) · Hepatology · doi:10.1002/hep.23633 · Cited by 106

Authors: Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W.
Affiliations: Norton Healthcare (US)
From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder...
ORCID: Moore, Malcolm J.
Goldstein, David
Hamm, John
Hecht, Joel R.
Au, Heather J.
Wolff, Robert A.
Ding, Keyue
Clark, Gary
Parulekar, Wendy
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2007-05-20
Volume: 25
Issue: 15
Pages: 1960-1966
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2006.07.9525
OpenAlex: W2158134441
Cited by: 3,848
References: 49
Citations by year: 2026: 45 · 2025: 62 · 2024: 123 · 2023: 113 · 2022: 129 · 2021: 178 · 2020: 159 · 2019: 170 · 2018: 204 · 2017: 217 · 2016: 242 · 2015: 275 · 2014: 274 · 2013: 251 · 2012: 268
FWCI: 133.78
Type: journal article
Language: en
Update notices: new_edition (2023-10-17)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: erlotinib, gemcitabine, advanced pancreatic cancer, targeted therapy, overall survival, progression-free survival, metastatic pancreatic cancer, combination chemotherapy, adverse events
MeSH terms: Erlotinib Hydrochloride, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Double-Blind Method, Female, Humans, International Agencies, Male, Middle Aged, Pancreatic Neoplasms, Placebos, Prognosis, Quinazolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks